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Abstract
Background—Only a few studies have explored the relation between coffee and tea intake and
head and neck (HN) cancers, with inconsistent results.
Methods—We pooled individual-level data from nine case-control studies of HN cancers,
including 5139 cases and 9028 controls. Logistic regression was used to estimate odds ratios (OR)
and 95% confidence intervals (CI) adjusting for potential confounders.
Results—Caffeinated coffee intake was inversely related with the risk of cancer of the oral
cavity and pharynx (OP): the ORs were 0.96 (95% CI 0.94–0.98) for an increment of one cup per
day and 0.61 (95% CI 0.47–0.80) in drinkers of >4 cups per day vs. non-drinkers. This latter
estimate was consistent for different anatomical sites (ORs were 0.46, 95%CI 0.30–0.71 for oral
cavity, 0.58, 95% CI 0.41–0.82 for oropharyngeal/hypopharyngeal and 0.61, 95% CI 0.37–1.01
for OP not otherwise specified), and across strata of selected covariates. No association of
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caffeinated coffee drinking was found with laryngeal cancer (OR=0.96, 95% CI 0.64–1.45 in
drinkers of >4 cups per day vs. non-drinkers). Data on decaffeinated coffee were too sparse for
detailed analysis, but indicated no increased risk. Tea intake was not associated with HN cancer
risk (OR=0.99, 95% CI 0.89–1.11 for drinkers vs. non-drinkers).
Conclusions—This pooled-analysis of case-control studies support the hypothesis of an inverse
association between caffeinated coffee drinking and OP cancer risk.
Impact—Given widespread use of coffee and the relatively high incidence and low survival of
HN cancers, the observed inverse association may have appreciable public health relevance.
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INTRODUCTION
Tobacco smoking and alcohol drinking are the major risk factors for cancers of the oral
cavity and pharynx (OP) and of the larynx (head and neck, HN, cancers) and together are
responsible of about 75% of cases diagnosed in North America and Europe (1,2); however,
other dietary and lifestyle factors, including other types of beverages, such as matè (3), may
also play a role (4). Tea and coffee are the most common hot beverages in the world (5). In
1990 the International Agency for Research on Cancer (IARC) evaluated the evidence of an
association between coffee intake and HN cancers to be inadequate to reach a conclusion,
based on results of six case-control studies (5). Since then, a possible association between
coffee intake and OP cancer risk was examined in at least two other prospective studies (6,7)
and several case-control studies (8–21). Two cohort (6,7) and three case-control studies
(10,12,19) reported some inverse relation, but most investigations reported inconsistent
results, partly due to the limited number of cases included in each study and the different
grouping of various HN cancers. One cohort study (22) and five case-control studies
considered the association between coffee intake and laryngeal cancer risk (14,23–26), and
overall showed no relation. At least two studies considered upper aerodigestive tract cancers
all together, including cancer of the oesophagus besides HN: a multicenter case-control
study, conducted in several European countries (Alcohol-Related Cancers And Genetic
susceptibility in Europe, ARCAGE) (27), and a prospective study among Hawaii Japanese
men (28): both found no consistent association with coffee drinking.
With reference to decaffeinated coffee, only one study considered HN cancers and found no
consistent association (19).
Likewise, one prospective (29) and several case-control studies (9,13–15,19,21,24), found
no material association between tea intake and HN cancer risk, while a prospective study
among Hawaii Japanese men (28) and the ARCAGE study (27) found an inverse relation.
Given the persistent uncertainties on the issue, we considered the relationship between
caffeinated, decaffeinated coffee and tea drinking and the risk of HN cancers using data
from a pooled-analysis of studies collected by the International Head and Neck Cancer
Epidemiology (INHANCE) consortium (30).
METHODS
The INHANCE consortium includes 33 epidemiologic studies providing data on 24,571
cases of HN cancers, and 33,013 controls, from many countries and regions, including
carcinomas of the oral cavity and pharynx, and larynx, and excluding lymphomas and
sarcomas, and cancers of the nasopharynx and salivary glands (30). Among the 33 studies,
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23 had no information on coffee nor tea drinking and thus could not be included in this
investigation. Another study was excluded because data on caffeinated coffee and tea
amount were missing for 46% and 67% of cases and 28% and 51% of controls, respectively
(31). Therefore, nine studies reporting information on caffeinated coffee, decaffeinated
coffee or tea drinking were included. All the nine case-control studies included OP cancer
and 7 studies included also laryngeal cancer. The characteristics of the studies are reported
in Table 1.
Cases were subdivided in the following sites: 1) oral cavity (including lip, tongue, gum,
floor of mouth and hard palate); 2) oropharynx (including base of tongue, lingual tonsil, soft
palate, uvula, tonsil and oropharynx); 3) hypopharynx (including pyriform sinus); 4) oral
cavity, pharynx unspecified or overlapping (not otherwise specified, NOS); 5) larynx
(including glottis, supraglottis and subglottis); 6) HN cancers unspecified (including
overlapping lesions not listed above).
This pooled-analysis is based on a total of 3915 cases of cancer of the OP (1191 of the oral
cavity, 2112 of oropharynx/hypopharynx and 612 of OP NOS) and 9028 controls from 9
studies (1,32–39), and 1224 cases of cancer of the larynx and 7239 controls from 7 studies
(32–38).
Controls were patients in hospital for acute, non neoplastic diseases, not related to tobacco
smoking and alcohol drinking, in five studies (32–35,38); and they were population controls
in the other studies (1,36,37,39). Two studies were multicenter themselves (1,34) (Table 1).
In the present report, the Italian multicentric study includes also the most recent data from
Milan (40). Results on coffee drinking from four studies included in this analysis have
already been published separately (1,32,34,35).
Face-to-face interviews were conducted in all studies. Informed consent was obtained from
all study subjects, and the investigations were approved by relevant ethic committees
according to the rules of each country and time period. Blank questionnaires were collected
from all the individual studies to assess the comparability of all data collected and of the
wording of the interview questions among the studies. Data from individual studies were
checked for inconsistencies, pooled in a standardized way into a common database including
a range of sociodemographic, behavioural, lifestyle and health information (30).
The questions about caffeinated, decaffeinated coffee and tea drinking were similar across
studies, although the exact wording differed. The information was collected as cups of
caffeinated, decaffeinated coffee or tea per day in four studies (32,33,37,39), per week in
two studies (34,35) and per month in one study (38), and as open questions for two studies
(1,36). The information across the studies was then converted into the variables “cups of
caffeinated coffee per day”, “cups of decaffeinated coffee per day” and “cups of tea per
day”.
Statistical analysis
The association between HN cancers and caffeinated coffee, decaffeinated coffee or tea
intake was assessed by estimating odds ratios (OR) and the corresponding 95% confidence
intervals (CI) using unconditional logistic regression models. All the models included study
centre, age (quinquennia, categorically), sex, education level (no formal education, less than
junior high school, some high school, high-school graduate, vocational/some college,
college graduate/postgraduate), race/ethnicity (non-Hispanic White, Black, Hispanic/Latino,
other), cigarette smoking (never, 1–10, 11–20, 21–30, 31–40, 41–50, >50 packs/year,
categorically), duration of cigar smoking (continuously), duration of pipe smoking
(continuously), alcohol drinking (non drinkers, >0–1, >1–3, >3–8, >8–18, >18–40, >40–75,
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>75–115, >115–155, >155 ml per day, categorically), body weight (quartiles, categorically),
and vegetable and fruit consumption (quartiles of intake, categorically). For subjects with
missing education level (388 cases and 250 controls), we applied multiple imputation (5
imputations) with the PROC MI procedure in SAS. To calculate summary estimates, the
study specific estimates were included in a two-stage random-effects logistic regression
model with the maximum likelihood estimator. Pooled ORs were also estimated with a
fixed-effects logistic regression model. We tested for heterogeneity among the study ORs
using a likelihood ratio test comparing a model that included the product terms between
each study (other than the reference study) with the variable of interest and a model without
a product term, for the risk of HN cancers combined and of each anatomical subsite. The
likelihood ratio test was assessed on the category of intake. We used the random-effects (41)
estimates when heterogeneity was detected (p<0.05), and the fixed-effects estimates
otherwise. We also conducted an influence analysis, in which each study was excluded one
at time to ensure that the statistical significance and magnitude of the overall estimates were
not dependent on any one study.
The OR for consumption of more than 4 cups per day of caffeinated coffee was also
calculated in strata of age, sex, geographical region, education, tobacco consumption,
alcohol consumption and vegetable and fruit intake. In stratified analyses, light tobacco
users were smokers of ≤20 pack-year equivalent (combination of pack-years of cigarettes
and equivalent amount of cigars or pipe). Heavy tobacco users were smokers of >20 pack-
year equivalent. Light alcohol drinkers were drinkers of <3 drinks per day, and heavy
alcohol drinkers were those drinking ≥3 drinks per day.
RESULTS
Table 1 presents the characteristics of the nine case-control studies included in the pooled
analysis. Of them, five were hospital-based and four were population-based. Four studies
were conducted in Europe, four in North America and one in Central America. The North
American multicentre study (1) and the Central American study (39) did not include
laryngeal cancer.
The distribution of cases at various organs within HN and controls according to age, sex and
other selected covariates is shown in Table 2. Males were 76% of OP and 90% of laryngeal
cancer cases, and non-Hispanic Whites were 86% and 95%, respectively. Cases were less
educated than controls, more often smokers and heavy alcohol drinkers.
The ORs of HN cancer for consumption of caffeinated coffee, decaffeinated coffee and tea
are reported in Table 3. Compared with non drinkers, the ORs of OP cancer combined were
0.88 (95% CI: 0.62–1.25) for <3 cups of caffeinated coffee per day, 0.78 (95% CI: 0.49–
1.24) for 3 to 4 cups per day and 0.61 (95% CI: 0.47–0.80) for >4 cups per day (p-value of
test for linear trend: <0.01). The ORs among caffeinated coffee drinkers of >4 cups per day,
based on nine studies, were 0.46 (95% CI: 0.30–0.71) for oral, 0.58 (95% CI: 0.41–0.82) for
oropharyngeal/hypopharyngeal, and 0.61 (95% CI: 0.37–1.01) for OP NOS cancer (p-value
of tests for linear trend: <0.01, 0.02 and <0.01). The corresponding OR for laryngeal cancer,
based on seven studies was 0.96 (95% CI: 0.64–1.45). The ORs for an increment of one cup
per day were 0.96 (95% CI: 0.94–0.98) for OP cancer (0.96 (95% CI: 0.92–0.99) for cancer
of the oral cavity, 0.95 (95% CI: 0.93–0.98) for cancer of the oropharynx/hypopharynx and
0.96 (95% CI: 0.91–1.00) for OP NOS cancer), and 0.99 (95% CI: 0.95–1.04) for laryngeal
cancer. Further adjustment for former smoking did not materially change the results.
Information on decaffeinated coffee derived from six studies for either OP or laryngeal
cancers. Decaffeinated coffee was consumed by 11–15% of cases of OP cancer and by 12%
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of controls, with corresponding ORs of 1.05 (95% CI 0.85–1.29) for OP cancer, 1.17 (95%
CI 0.81–1.69) for oral, 0.94 (95% CI 0.72–1.23) for oropharyngeal/hypopharyngeal, and
1.40 (95% CI 0.93–2.12) for OP NOS cancer. Eight percent of cases of laryngeal cancer
consumed decaffeinated coffee. The corresponding OR for laryngeal cancer was 0.96 (95%
CI 0.41–2.22). The estimates were not different for consumption of <1 cup and ≥1 cup per
day. When we combined information on types of coffee consumed, 73% of cases of OP
cancer and 74% of controls were drinkers of caffeinated coffee alone, 4% of both cases and
controls were drinkers of decaffeinated coffee alone, and 8% of cases and controls drank
both caffeinated and decaffeinated coffee. As compared to non drinkers of any type of
coffee, the ORs for drinkers of both types of coffee were 0.79 (95% CI: 0.51–1.21) for OP
cancer, 0.72 (95% CI: 0.39–1.33) for oral, 0.80 (95% CI: 0.46–1.38) for oropharyngeal/
hypopharyngeal and 1.11 (95% CI: 0.54–2.29) for OP NOS cancer. The corresponding OR
for laryngeal cancer was 0.92 (95% CI: 0.34–2.53).
Compared to tea non drinkers, the ORs for tea drinkers were 0.99 (95% CI: 0.89–1.11) for
OP cancer, 1.06 for oral (95% CI: 0.88–1.27), 0.93 (95% CI: 0.81–1.06) for oropharyngeal/
hypopharyngeal, 1.10 (95% CI: 0.88–1.39) for OP NOS (based on nine studies), and 0.97
(95% CI: 0.80–1.18) for laryngeal cancer (based on seven studies).
Figure 1 shows the study specific estimates for the relation between amount of caffeinated
coffee consumption and OP cancer. Panel A gives the ORs for >0–<3 cups per day, panel B
gives the ORs for ≥3–≤4 cups per day, and panel C gives the ORs for >4 cups per day,
versus non drinkers of caffeinated coffee. For an intake of >4 cups per day of caffeinated
coffee, the ORs of OP cancer were below unity in seven studies (significant in two studies)
and above unity in two studies (non significant), resulting in a summary OR of 0.61 (95%
CI: 0.49–0.77) with p-value for heterogeneity equal to 0.57.
Figure 2 shows the study specific estimates for the relation between levels of caffeinated
coffee consumption and laryngeal cancer. Panel A gives the ORs for >0–<3 cups per day,
panel B gives the ORs for ≥3–≤4 cups per day, and panel C gives the ORs for >4 cups per
day, versus non drinkers of caffeinated coffee. For an intake of >4 cups per day, the ORs of
laryngeal cancer were close to unity in two studies, above unity in one study (non
significant), and below unity in three studies (significant in one), resulting in a summary OR
of 0.94 (95% CI: 0.62–1.42) with p-value for heterogeneity equal to 0.07. In sensitivity
analysis, summary ORs were calculated after exclusion of one study at a time. These
analyses did not reveal any notable change in the estimates, with ORs for OP cancer varying
between 0.58 and 0.68.
Table 4 reports the ORs of OP cancer for caffeinated coffee intake of >4 cups per day in
strata of selected covariates. There was no heterogeneity across strata of age, sex,
geographic region, education, tobacco smoking, alcohol drinking, vegetable and fruit intake,
and type of controls. However, numbers of cases were small among never and light tobacco
smokers.
DISCUSSION
In this pooled analysis of case-control studies, caffeinated coffee was inversely related with
the risk of OP cancer. The protection was similar across the oral cavity and pharyngeal sites,
with a substantial amount of heterogeneity between studies. No association of caffeinated
coffee drinking was found with cancer of the larynx. Data on decaffeinated coffee and tea
indicated a lack of material association. However, for decaffeinated coffee data were
limited, as both the prevalence of consumption and the amount consumed by drinkers were
low.
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Risk estimates of OP cancer for caffeinated coffee drinking were heterogeneous between
studies. Chemical composition of coffee beverages varies according to variety of the plant
(Arabica or Robusta) and preparation, but most studies had inadequate information on these
issues. Another source of heterogeneity is that some subjects with low or irregular
consumption of coffee may have been included among non drinkers because of the way the
unexposed group was defined in some studies. In fact, results were heterogeneous among
intermediate levels of consumption, but not among subjects with high consumption. This
possible misclassification, however, if anything, could have attenuated the inverse
association.
Other sources of heterogeneity are the different patterns of alcohol drinking and tobacco
smoking in various populations, positively correlated with both coffee intake and HN cancer
risk (42–44). However, the inverse association was similar in strata of tobacco smoking and
alcohol drinking. When we stratified for geographic region, no heterogeneity was detected
within European studies and within American studies, separately, indicating that it could be
at least partly explained by different modalities of consumption among European and US
populations (e.g., variety of coffee, type of processing and/or preparation, patterns of
consumption, etc.). In a sensitivity analysis, exclusion of each study from the pooled-
analysis did not materially change the summary estimates, showing that results were not
driven by any single study. Recall of coffee drinking has been shown satisfactorily
reproducible and valid (45–48), and should not be different on the basis of the disease status
or among various types of controls, as coffee is not commonly known to affect OP cancer
risk.
The presence of pre-neoplastic changes in the oral cavity or symptoms of the disease may
cause changes in coffee or tea drinking among the cases, notably a decrease among cases
due to high temperature of coffee or tea (reverse causation). However, the difference in
results between caffeinated coffee and tea intake would suggest that reverse causality due to
disease-related change in drinking patterns is not the main reason for the observed
associations for caffeinated coffee intake. Additionally, limited findings from cohort studies
– where information on coffee drinking is collected several years before diagnosis – weigh
against a relevant role of reverse causation. There are, in fact, two Norwegian cohorts: one
cohort (22) included 38 cases of OP cancer and found a relative risk (RR) of 0.73 for
drinkers of 7 or more cups per day of coffee compared to 2 or less; the other cohort included
33 cases of cancers and found a RR of 0.5 for drinkers of 7 or more cups per day, with a
significant inverse trend in risk (6). A third cohort study was based on the Miyagi Cohort in
Japan, included 48 cases and found a RR of 0.35 (95% CI: 0.16–0.77) for drinkers of one or
more cups per day (7). Thus, overall the limited evidence from cohort studies suggests a
decreased risk for high coffee intake, although publication bias cannot be excluded.
In this analysis, the risk estimates did not materially change after adjustment for body
weight and for vegetable and fruit consumption, which have been inversely associated with
oral cancer in several studies (49). More important, caffeinated coffee drinking was
moderately correlated with tobacco (r=0.24, p<0.001) and alcohol (r=0.14, p<0.001)
consumption. However, careful allowance for alcohol drinking and tobacco smoking did not
materially modify any of the risk estimates, indicating that residual confounding is not a
plausible explanation of the inverse relation between caffeinated coffee and OP cancer.
Additionally, assuming that coffee drinkers also smoke and drink more, any residual
confounding would result in a positive bias away from the null, which we did not observe in
our study. Information was not available on human papillomavirus (HPV) infection, which
has been causally associated with oropharyngeal cancer (50), but there is no reason to think
that coffee intake is associated with HPV infection. Another limitation of this study is the
lack of good quality data on duration of coffee drinking or other time-related factors of the
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exposure in several studies, which did not allow investigation of these issues in the pooled
analysis.
With reference to other studies investigating the relation of coffee drinking and HN cancer
risk, of the at least eleven case-control studies not included in the INHANCE consortium
(8,9,13–16,18,20,21,51), one study from the USA (13), one from Brazil (14) and one from
Montenegro (20) considering OP cancer, and six studies considering oral or hypopharyngeal
cancer (9,15,16,18,21,51) found no significant association with coffee drinking, but the
point estimates were below unity in several of them. Each study, however, was not large
enough to have adequate statistical power to detect a relatively weak association and often
did not focus on coffee or had no adjustment for tobacco smoking and alcohol drinking.
When we conducted a summary meta-analysis of the six most informative studies not
included in the INHANCE consortium, i.e., those with a quantification of the amount of
coffee (one cohort and five case-control, for a total of 1628 cases) (7,13–16,21), the
summary RR for the highest category of coffee consumption as compared to the lowest one
(as categorized in each study) was 0.72 (95% CI 0.55–0.95).
As for laryngeal cancer risk, results of studies not included in this pooled-analysis were
inconsistent, and overall compatible with no relation. One Norwegian cohort study (22)
found an inverse relation of laryngeal cancer with coffee intake, two case-control studies
(8,26) found an increased risk and one prospective (6) and two case-control studies (14,24)
found no relation.
For both OP and laryngeal cancers, the few other published data on decaffeinated coffee
consumption are inadequate for any meaningful inference (52).
With reference to tea intake, one Japanese prospective study (29) on oral cancer, four case-
control studies on OP/oral cancers (9,13–15) and two case-control studies on laryngeal
cancer (14,24) found no significant relation, similarly to the results of our pooled-analysis.
The World Cancer Research Fund Expert Report concluded that the evidence for a relation
between tea consumption and HN cancers is too limited to draw any conclusion (49).
Support for a real inverse association between caffeinated coffee intake and OP cancer
comes from the significant inverse dose-relation in a subset of studies, the consistent relation
across strata of potential confounders and effect modifiers, and the consistent association in
European and American populations. Furthermore, the absence of a relation observed in the
same studies between caffeinated coffee intake and the risk of laryngeal cancer, which
shares similar risk factors of OP cancer (4,23,24), support a real association between
caffeinated coffee intake and the risk of OP cancer. The lack of association with tea drinking
argues against reverse causality and report bias too, though tea is generally less consumed
than caffeinated coffee in these populations and it is likely to be more misclassified.
The inverse relationship between caffeinated coffee drinking and OP cancer can be related
to various components of coffee. Besides caffeine, coffee contains more than a thousand
chemicals (5), some of which have antioxidant and antimutagenic activities in animal
models and cell culture systems (53). These include several phenolic compounds (such as
chlorogenic, caffeic, ferulic and cumaric acids), melanoidins and diterpenes (such as cafestol
and kahweol) (54,55) whose concentration in the beverage varies depending on type of raw
coffee (Arabica or Robusta), roasting and preparation, as unfiltered coffee contains less
amounts of lipid component, such as diterpenes (56). In particular, cafestol and kahweol
may reduce the genotoxicity of some carcinogens (53), and may activate enzymes involved
in cancerogenic detoxification (57,58), such as glutathione-S-transferase and inhibiting N-
acetyltransferase (59). Still, no definite biological mechanism of the potential healthy role of
coffee on HN cancers is available (52). Coffee drinking has also been inversely related to
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colorectal cancer (60), liver cirrhosis and cancer (52), and endometrial cancer (61), again in
the absence of a clear interpretation.
In conclusion, the results of this pooled-analysis of case-control studies support the
hypothesis of an inverse association between caffeinated coffee drinking and OP cancer risk,
and provide a more precise estimate of the magnitude of the effect. Bias, confounding and
reverse causality, however, cannot be excluded. Given widespread use of coffee and the
high incidence and low survival of HN cancers (62), it is important to conclusively establish
whether the observed association between caffeinated coffee drinking and HN cancer risk is
causal as this would have appreciable public health relevance, though alcohol and tobacco
remain the key risk factors for OP cancer in most population (1).
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Figure 1.
Study specific and pooled estimates of OP cancer for drinkers of caffeinated coffee versus
non drinkers
NOTE In Panel B the study by Peters et al 2005 is missing because no subjects consumed
<=3->=4 cups of caffeinated coffee per day, due to the ordinal response scale used (i.e., 2–3
cups per day, 3–4 cups per day). Small differences in the estimates between the figure and
Table 3 are due to rounding off of data.
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Figure 2.
Study specific and pooled estimates of laringeal cancer for drinkers of caffeinated coffee
versus non drinkers
NOTE In Panel B two studies are missing. Study by Peters et al. 2005 is missing because no
subjects consumed <=3->=4 cups of caffeinated coffee per day, due to the ordinal response
scale used (i.e., 2–3 cups per day, 3–4 cups per day); study by Schantz et al 1997 is missing
because the OR was not estimable, respectively. Small differences in the estimates between
the figure and Table 3 are due to rounding off of data.
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TABLE 4
Distribution of cases of oral cavity and pharyngeal cancer and controls, and corresponding odds ratios (OR)a
and 95% confidence intervals (CI), for drinking >4 cups per day of caffeinated coffee vs. non drinkers, in
strata of selected covariates
Oral cavity and pharynx cancer
Controls (n=830) Cases (n=525) OR (95% CI) p for heterogeneityb
Age (years)
 <55 376 184 0.60 (0.41–0.88) 0.06
 ≥ 55 454 341 0.55 (0.40–0.75) 0.02
Sex
 Men 645 412 0.59 (0.42–0.81) <0.01
 Women 185 113 0.46 (0.27–0.78) <0.01
Geographic regionc
 Europe 412 132 0.63 (0.43–0.92) 0.07
 America 418 393 0.60 (0.45–0.80) 0.11
Educationd
 <high school graduate 317 139 0.55 (0.33–0.93) <0.01
 ≥high school graduate 508 383 0.65 (0.45–0.93) <0.01
Tobacco consumptiond,e
 Never tobacco users 299 69 0.72 (0.31–1.64) <0.01
 Light tobacco users 322 164 0.53 (0.25–1.13) 0.03
 Heavy tobacco users 205 290 0.51 (0.35–0.76) <0.01
Alcohol consumptiond,f
 Never or Light drinkers 566 227 0.59 (0.42–0.85) <0.01
  Heavy drinkers 243 286 0.61 (0.42–0.85) <0.01
Vegetable intake
 <median 388 307 0.59 (0.37–0.92) <0.01
 ≥median 442 218 0.60 (0.39–0.92) <0.01
Fruit intaked
 <median 429 354 0.52 (0.36–0.74) <0.01
 ≥median 401 167 0.65 (0.41–1.02) <0.01
Type of controls
 Hospital based 418 141 0.65 (0.38–1.11) <0.01
 Population based 412 384 0.58 (0.44–0.78) 0.20
a
We used the random effects estimates when heterogeneity was detected, and the fixed-effects estimates otherwise. Adjusted for age, sex, race/
ethnicity, education, study, cigarette smoking (pack-years), duration of cigar smoking, duration of pipe smoking, alcohol intake, weight, vegetable
and fruit intake (as appropriate). Reference category was coffee non drinkers in each stratum.
b
Between studies
c
Europe included two studies from Italy (32,34), one from France (33) and one from Switzerland (35). America included four studies from USA
(1,36–38) and one from Puerto Rico (39).
d
The sum does not add up to the total because of some missing values
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2011 July 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Galeone et al. Page 22
e
Light tobacco users were smokers of ≤20 pack-year equivalent (combination of pack-years of cigarettes and equivalent amount of cigars or pipe).
Heavy tobacco users were smokers of >20 pack-year equivalent.
f
Never/Light drinkers were drinkers of <3 drinks per day of alcoholic beverages and heavy drinkers those consuming ≥3 drinks per day.
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